Recombinant KLK8/Kallikrein 8 Monoclonal Antibody (AN300243P)
For research use only.
| Verified Samples | Verified Samples in WB: A431 |
| Dilution | WB 1:500-1:1000, |
| Isotype | IgG |
| Host | Rabbit |
| Reactivity | Human |
| Applications | WB |
| Clonality | Monoclonal |
| Immunogen | Recombinant Human KLK8 / Kallikrein 8 Protein |
| Abbre | KLK8 |
| Synonyms | KLK, UNQ, PRO, Kallikrein, Serine Protease, TADG, PRSS, Serine Protease TADG, hK8, Kallikrein-8, Neuropsin, NP, Ovasin, Serine Protease 19, Serine Protease TADG-14, Tumor-Associated Differentially Expressed Gene 14 Protein, NRPN, PRSS19, TADG14, KLK8, UNQ283, PRO322, Brain serine protease 1, BSP1, HNP, homolog of, HPN, included, Kallikrein 8 (neuropsin/ovasin), Kallikrein related peptidase 8, Kallikrein8, KLK 8, KLK8 protein type 1, KLK8 protein type 2, mouse, neuropsin type 1, Neuropsin type 2, Protease serine 19, PRSS 19, Serine protease kallikrein, Serine protease kallikrein/ovasin/neuropsin, Serine protease TADG 14, Serine protease TADG14, TADG 14, Tumor associated differentially expressed gene 14, Tumor associated differentially expressed gene 14 protein |
| Swissprot | |
| Calculated MW | 28 kDa |
| Observed MW |
35 kDa
The actual band is not consistent with the expectation.
Western blotting is a method for detecting a certain protein in a complex sample based on the specific binding of antigen and antibody. Different proteins can be divided into bands based on different mobility rates. The mobility is affected by many factors, which may cause the observed band size to be inconsistent with the expected size. The common factors include: 1. Post-translational modifications: For example, modifications such as glycosylation, phosphorylation, methylation, and acetylation will increase the molecular weight of the protein. 2. Splicing variants: Different expression patterns of various mRNA splicing bodies may produce proteins of different sizes. 3. Post-translational cleavage: Many proteins are first synthesized into precursor proteins and then cleaved to form active forms, such as COL1A1. 4. Relative charge: the composition of amino acids (the proportion of charged amino acids and uncharged amino acids). 5. Formation of multimers: For example, in protein dimer, strong interactions between proteins can cause the bands to be larger. However, the use of reducing conditions can usually avoid the formation of multimers. If a protein in a sample has different modified forms at the same time, multiple bands may be detected on the membrane. |
| Concentration | 1 mg/mL |
| Buffer | 0.2 μm filtered solution in PBS |
| Purification Method | Protein A |
| Research Areas | Signal Transduction, Cancer, Cell Biology |
| Clone No. | 5F6 |
| Conjugation | Unconjugated |
| Storage | This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free. Avoid repeated freeze-thaw cycles. |
| Shipping | Ice bag |
| background | Kallikrein-8, also known as Neuropsin, Serine protease 19, Serine protease TADG-14, Tumor-associated differentially expressed gene 14 protein, and KLK8 is a secreted protein that belongs to the peptidase S1 family and Kallikrein subfamily. It is a serine protease that is capable of degrading some proteins such as casein, fibrinogen, kininogen, fibronectin, and collagen type IV. Kallikrein-8/KLK8 plays a role in the formation and maturation of orphan and small synaptic boutons in the Schaffer-collateral pathway. It regulates Schaffer-collateral long-term potentiation in the hippocampus and is required for memory acquisition and synaptic plasticity. It is involved in skin desquamation and keratinocyte proliferation and plays a role in the secondary phase of pathogenesis following spinal cord injury. It also cleaves L1CAM in response to increased neural activity. It induces neurite outgrowth and fasciculation of cultured hippocampal neurons. Kallikrein-8/KLK8 is expressed at high levels in serum, ascites fluid, and tumor cytosol of advanced-stage ovarian cancer patients and may serve as a marker of ovarian cancer. Kallikrein-8/KLK8 may have potential clinical value for disease diagnosis or prognosis and it may also be a useful therapeutic target. |
Other Clones
{{antibodyDetailsPage.numTotal}} Results
-
{{item.title}}
Citations ({{item.publications_count}}) Manual MSDS
Cat.No.：{{item.cat}}
{{index}} {{goods_show_value}}
Other Formats
{{formatDetailsPage.numTotal}} Results
Unconjugated
-
{{item.title}}
Citations ({{item.publications_count}}) Manual MSDS
Cat.No.：{{item.cat}}
{{index}} {{goods_show_value}}
-
IF：{{item.impact}}
Journal：{{item.journal}} ({{item.year}})
DOI：{{item.doi}}Reactivity：{{item.species}}
Sample Type：{{item.organization}}
-
Q{{(FAQpage.currentPage - 1)*pageSize+index+1}}:{{item.name}}
